Cargando…
Mucosal Delivery of RNAi Therapeutics
The effectiveness of RNA interference-based drugs is dependent on accumulation at the target site in therapeutically relevant amounts. Local administration to the mucosal surfaces lining the respiratory, gastrointestinal and genitourinary tracts allows access into diseased areas without the necessit...
Autores principales: | González, Borja Ballarín, Nielsen, Ebbe Bech, Thomsen, Troels Bo, Howard, Kenneth A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121168/ http://dx.doi.org/10.1007/978-1-4614-4744-3_5 |
Ejemplares similares
-
Clinical translation of RNAi-based treatments for respiratory diseases
por: Ballarín-González, Borja, et al.
Publicado: (2012) -
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
por: Zhou, Jiehua, et al.
Publicado: (2013) -
Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside
por: Qiu, Yingshan, et al.
Publicado: (2016) -
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
por: Lage, Hermann, et al.
Publicado: (2010) -
Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics
por: Gentile, Emanuela, et al.
Publicado: (2017)